The evolution of monoclonal antibodies

    loading  Checking for direct PDF access through Ovid


Since the Milstein's explosive generation experimentally of monocloncal antibodies both the ability to probe experimentally and deliver therapeutically has created a wave of utilising ‘biologics’ for therapeutic gain. From understanding of inflammatory responses in the eye during uveitis we have been able to iteratively target either cytokine responses, cell responses or inhibit activation of cells. The introduction will give a brief overview of developments, targets and the future in a more specified and personalised approach to harnessing the strengths of biologic therapy.

Related Topics

    loading  Loading Related Articles